Tuesday, 04 Nov 2025

FDA approves AJOVY for paediatric migraine prevention

Written by
PharmaTimes
Published
Teva’s CGRP therapy becomes first approved option for children and adolescent Teva’s CGRP therapy becomes first approved option for children and adolescent
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago